In this study, we investigate the clinical implications of varying outcomes relative to BUD31 expression levels by using a cohort of tissue microarrays (TMAs) and data from The Cancer Genome Atlas (PRAD-TCGA) to analyze how expression of this gene varies in patients with different tumor stages and mutations. This evidence concerns the gene BUD31 and neoplasm.